Recap: Akoya Biosciences Q3 Earnings
Portfolio Pulse from Benzinga Insights
Akoya Biosciences (NASDAQ:AKYA) reported its Q3 earnings, beating estimated earnings by 29.73% with an EPS of $-0.26 versus an estimate of $-0.37. Revenue was up $6.36 million from the same period last year. Last quarter, the company missed on EPS by $0.07, which was followed by a 3.01% increase in the share price the next day.
November 08, 2023 | 9:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Akoya Biosciences reported better than expected Q3 earnings, with an EPS of $-0.26, beating estimates by 29.73%. Revenue increased by $6.36 million YoY. Despite missing EPS last quarter, the share price increased by 3.01%.
Akoya Biosciences reported a strong Q3 earnings, beating estimates by a significant margin. This positive news is likely to boost investor confidence and could lead to a short-term increase in the stock price, similar to the 3.01% increase observed after the last quarter's earnings release despite an EPS miss.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100